A personalized approach to COPD management is needed
KEY POINT
A small decline in lung function with no change in the rate of exacerbations was observed in patients with infrequent exacerbations and moderate to severe chronic obstructive pulmonary disease (COPD) who had been on long-term triple therapy and were subsequently de-escalated to dual therapy, according to data published in the American Journal of Respiratory and Critical Care Medicine.
SOURCES
Chapman KR, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329–39.
Tashkin, DP. To withdraw or not to withdraw inhaled corticosteroids from triple therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2018;198(3):292–4.
